Emcure Pharmaceuticals partners with Gilead Sciences to produce HIV prevention drug Lenacapavir
Emcure Pharmaceuticals on Thursday announced a royalty-free voluntary licensing agreement with Gilead Sciences Ireland UC, a ...
Hosted on MSN3mon
Dr Reddy's, Hetero ink royalty-free voluntary licencing pacts with Gilead Sciences for HIV drug Lenacapavir
royalty-free voluntary licencing agreements with Gilead Sciences Ireland UC to manufacture and distribute the latter's human immunodeficiency virus (HIV) drug Lenacapavir in India and 120 low- and ...
FiercePharma10d
Gilead settles with US government in long-running patent dust-up over PrEP meds Truvada, Descovy
Terms of the deal were not disclosed in the case, which involved the government’s patents on Gilead’s HIV drugs Truvada and ...
Gilead, LEO Pharma partner to develop programs for inflammatory diseases
Gilead Sciences said on Saturday that it entered into a partnership with Denmark's LEO Pharma to develop programs to treat ...
pharmaphorum1d
NICE recommends first CAR-T cell therapy on NHS in England
Dr Véronique Walsh, VP and GM at Gilead Sciences UK & Ireland, commented: “This news comes at a time when new hospitals are preparing to deliver CAR-T cell therapies and will mean that ...
Business Wire15d
Gilead and LEO Pharma Enter Into Strategic Partnership to Accelerate Development of Oral STAT6 Program With Potential in Multiple Inflammatory Diseases
Gilead Sciences, Inc. (Nasdaq: GILD) and LEO Pharma today announced a strategic partnership to accelerate the development and ...
Gilead Sciences: Supreme Court Case and New Innovations Drive Buy Rating
Michael Yee, an analyst from Jefferies, maintained the Buy rating on Gilead Sciences (GILD – Research Report). The associated price target ...